Compare FLNC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNC | MESO |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 108 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2021 | 2005 |
| Metric | FLNC | MESO |
|---|---|---|
| Price | $7.86 | $14.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $15.71 | N/A |
| AVG Volume (30 Days) | ★ 7.2M | 160.8K |
| Earning Date | 05-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,830,000.00 | N/A |
| Revenue This Year | $51.23 | $629.74 |
| Revenue Next Year | $21.30 | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.01 | $13.05 |
| 52 Week High | $33.51 | $21.50 |
| Indicator | FLNC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 42.64 |
| Support Level | $7.01 | $14.18 |
| Resistance Level | $11.37 | $16.06 |
| Average True Range (ATR) | 0.41 | 0.42 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 25.72 | 30.73 |
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.